Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula: a Double-blind, Randomized, Controlled, International, Multi-centric Clinical Trial

NCT04358146 is registered in ClinicalTrials.gov with United Pharmaceuticals as lead sponsor.

NCT NCT04358146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04358146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula: a Double-blind, Randomized, Controlled, International, Multi-centric Clinical Trial
Lead sponsor
United Pharmaceuticals
Phase
Not applicable
Overall status
Recruiting
Start date
March 17, 2023
Completion date
December 3, 2026
Enrollment
346 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal reflux in children